Clinical trial NCT06979180: A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on the Regression of Abnormal Cervical Cells Caused by HPV.
Official title: A Randomized, Triple-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Papillex® on the Regression of Abnormal Cervical Cells Caused by HPV
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: CIN - Cervical Intraepithelial Neoplasia
CIN 1
CIN 2
HPV
Cervical Cells
Keywords: Cervical intraepithelial neoplasia
HPV
Papillex
Lead sponsor: Papillex Inc.
Sponsor class: INDUSTRY
First posted: 2025-05-18
Enrollment: 60
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to investigate the safety and efficacy of Papillex® on the regression of abnormal cervical cells caused by HPV in women with a cervical intraepithelial neoplasia (CIN) 1 or 2 diagnosis. The main question it aims to answer is:

Is there a difference in the proportion of participants with a regression in CIN based on histology or cytology from baseline at day 180 between Papillex® and placebo?

Participants will be asked to consume Papillex® or placebo for 180 days, complete questionnaires, a PAP smear, HPV test, and colonoscopy (where applicable).


Eligibility criteria: Inclusion Criteria:

1. Females between 25 and 60 years of age
2. Females not of child-bearing potential, defined as those who have undergone a permanent sterilization procedure (e.g. hysterectomy, bilateral oophorectomy or bilateral tubal occlusion) or have been post-menopausal for at least 1 year prior to screening Or,

   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), hormone implant (Norplant System) or intrauterine hormone-releasing system
   * Double-barrier method
   * Intrauterine devices
   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
   * Vasectomized partner, provided that partner is the sole sexual partner and that the vasectomised partner has received medical assessment of the surgical success
   * Abstinence
3. Must have CIN 1 or 2 diagnosis, based on histology within the past 18 months with confirmed abnormal cells based on cytology within 6 months, who are not indicated for treatment or current undergoing treatment
4. Willing to provide copies of pathology and cytology reports for eligibility confirmation
5. Positive for human papillomavirus (HPV)
6. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study
7. Willingness to avoid magnetic resonance imaging, computed tomography, X-ray, or other procedures with contrast media injection for 48 hr prior to study visits assessing micronutrient status
8. Willingness and ability to complete questionnaires and diaries associated with the study, and to complete all clinic visits and assessments
9. Provided voluntary, written, informed consent to participate in the study
10. Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI)

Exclusion Criteria:

1. Women who are pregnant, breast feeding, or planning to become pregnant during the study
2. Allergy, sensitivity, or intolerance preventing consumption of investigational product or placebo ingredients
3. Currently undergoing treatment for CIN, have received treatment (e.g., conization or loop electrosurgical excision procedure) within the last five years, or have active CIN 3
4. Concurrent uterine pathologies
5. History of hysterectomy or destructive therapy of the cervix
6. Cervical cancer
7. Unstable metabolic disease or chronic diseases as assessed by the QI
8. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3)
10. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
11. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
13. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
15. Individuals with an autoimmune disease or are immune compromised
16. Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
17. Self-reported confirmation of blood/bleeding disorders as assessed by the QI
18. Alcohol intake average of \>2 standard drinks per day as assessed by the QI
19. Alcohol or drug abuse within the last 12 months
20. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Section 7.3)
21. Clinically significant abnormal laboratory results at screening as assessed by the QI
22. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
23. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
24. Individuals who are cognitively impaired and/or who are unable to give informed consent
25. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

Primary outcomes:
measure: The difference in the proportion of participants with a regression in cervical intraepithelial neoplasia (CIN)
timeFrame: Day 0 to 180
Secondary outcomes:
measure: The difference in the proportion of participants with a regression in abnormal cells
timeFrame: Day 0 to 180
measure: The difference in the proportion of participants who move from human papillomavirus (HPV) positive to HPV negative
timeFrame: Day 0 to 180
measure: The difference in change in symptoms of abnormal cervical cells
timeFrame: Day 0 to 180
measure: The difference in change in Quality of life (QoL)
timeFrame: Day 0 to 180
measure: The difference in change in micronutrient status
timeFrame: Day 0 to 180
measure: The difference in change in immune cells
timeFrame: Day 0 to 180
measure: The difference in change in plasma concentrations
timeFrame: Day 0 to 180
Other outcomes:
measure: The difference in change in symptoms of abnormal cervical cells for participants who continue into the open label period
timeFrame: Day 180 to 360
measure: The difference in change in Quality of Life for participants who continue into the open label period
timeFrame: Day 180 to 360
measure: Incidence of post-emergent adverse events (AE)
timeFrame: Day 0 to 360
measure: Clinically relevant changes in blood pressure after supplementation
timeFrame: Day 0 to 180
measure: Clinically relevant changes in heart rate after supplementation
timeFrame: Day 0 to 180
measure: Clinically relevant changes in clinical chemistry after supplementation at Day 180
timeFrame: Day 0 to 180
measure: Clinically relevant changes in complete blood count after supplementation at Day 180
timeFrame: Day 0 to 180
Locations:
city: London
country: Canada
facility: KGK Science Inc.
state: Ontario
Study officials:
affiliation: KGK Science Inc.
name: David Crowley, MD
role: PRINCIPAL_INVESTIGATOR
References: